Clinical Trials Logo

Clinical Trial Summary

A Phase 2 study of Zandelisib with Venetoclax (VEN) and Rituximab (R) in subjects with Relapsed/Refractory CLL.


Clinical Trial Description

This is an open label Phase 2 clinical study of Zandelisib with Venetoclax (VEN) and Rituximab (R) in subjects with R/R CLL. VEN and R will be administered per standard of care. Subjects must have histologically confirmed relapsed/refractory CLL and received ≥1 lines of prior therapy A total 42 subjects will be enrolled and treated with zandelisib in combination with VEN + R. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05209308
Study type Interventional
Source MEI Pharma, Inc.
Contact MEI Pharma MEI Pharma
Phone 858-369-7100
Email [email protected]
Status Recruiting
Phase Phase 2
Start date September 2022
Completion date March 2026

See also
  Status Clinical Trial Phase
Active, not recruiting NCT02229422 - A Study of Obinutuzumab(GA101) in Combination With High-Dose Methylprednisolone(HDMP) in Chronic Lymphocytic Leukemia(CLL) Patients (GA101 & HDMP) Phase 1/Phase 2
Recruiting NCT03997968 - A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT01862445 - Retrospective Study: Efficacy and Safety of Chlorambucil + Rituximab in CLL Patients
Completed NCT00535873 - Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) Age 65 and Older Phase 2
Withdrawn NCT03639324 - Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL Phase 1
Recruiting NCT03868722 - Acalabrutinib and Venetoclax Treatment of Newly Diagnosed Patients With CLL at High Risk of Infection or Early Treatment Phase 2/Phase 3
Not yet recruiting NCT05517265 - Acalabrutinib in Patients With Chronic Lymphocytic Leukemia With Direct Oral Anticoagulation (CICERO)
Recruiting NCT04640909 - Impact of Treatment With Targeted Therapies on the Generation of CAR T Cells in CLL Patients N/A
Completed NCT01168921 - Phase II Eltrombopag in Chronic Lymphocytic Leukemia (CLL) Phase 2
Completed NCT00792077 - A Pilot Study to Investigate the Effect of Cytotoxic Therapy and/or Radiotherapy on Cancer Related Sleep Disturbances in CLL and Breast Cancer Patients Experiencing Fatigue Phase 2
Recruiting NCT05246345 - Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia
Terminated NCT01532635 - A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives Phase 2
Completed NCT01703364 - Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide in Untreated CLL Phase 1/Phase 2
Terminated NCT03572634 - Phase 1/2 Study of TP-0903 (an Inhibitor of AXL Kinase) in Patients With Previously Treated CLL Phase 1/Phase 2
Completed NCT03231579 - Chronic Lymphocytic Leukemia Electronic Patient Reported Outcomes Study
Completed NCT00636909 - Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders Phase 2
Active, not recruiting NCT03524235 - Haploidentical Stem Cell Transplant With Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL Phase 1
Active, not recruiting NCT04746092 - The Capability of Haemato-oncology Patients to Generate Antibodies Against COVID-19
Active, not recruiting NCT03283137 - Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL Phase 1
Recruiting NCT02377869 - Heavy Light Chain in Chronic Lymphocytic Leukemia N/A